Tutte le immagini(1)

Documenti fondamentali

Y0000829

Nilutamide

Name: Nilutamide
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione, Anandron, RU-23908

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):

C₁₂H₁₀F₃N₃O₄

Numero CAS:

63612-50-0

Peso molecolare:

317.22

Numero MDL:

MFCD00864670

Codice UNSPSC:

41116107

ID PubChem:

329831176

NACRES:

NA.24

Prodotti consigliati

Slide 1 of 1

1 of 1

Sigma-Aldrich

608661

Nitrogen-¹⁴N₂

Grado

pharmaceutical primary standard

Famiglia di API

nilutamide

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

CC1(C)NC(=O)N(c2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)C1=O

InChI

1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)
XWXYUMMDTVBTOU-UHFFFAOYSA-N

Informazioni sul gene

human ... AR(367)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Materiali di riferimento analitici per il CQ Pharma

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Nilutamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo

Descrizione

Determinazione del prezzo

Y0000894

Nilutamide impurity B, European Pharmacopoeia (EP) Reference Standard

Pittogrammi

GHS06,GHS08

Avvertenze

Danger

Indicazioni di pericolo

H301,H360

Consigli di prudenza

P201 - P301 + P310 + P330

Classi di pericolo

Acute Tox. 3 Oral - Repr. 1B

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.

Ravi A Madan et al.

Clinical cancer research : an official journal of the American Association for Cancer Research, 14(14), 4526-4531 (2008-07-17)

We reported previously the first randomized study of any kind in patients with nonmetastatic, castrate-resistant prostate cancer. The study employed vaccine, the hormone nilutamide, and the combined therapy (crossover for each arm) with an endpoint of time to progression. We

Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.

Richard Choo et al.

International journal of radiation oncology, biology, physics, 75(4), 983-989 (2009-05-05)

To determine the efficacy of a combined approach of radiotherapy (RT) plus 2-year androgen suppression (AS) as salvage treatment for prostate-specific antigen (PSA) relapse after radical prostatectomy (RP). Seventy-five patients with PSA relapse after RP were treated with salvage RT

A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.

Shan Lu et al.

Molecular cancer therapeutics, 6(7), 2057-2064 (2007-07-11)

The purpose of this study was to determine the effects of 6-amino-2-[2-(4-tert-butyl-phenoxy)-ethylsulfonyl]-1H-pyrimidine-4-one (DL3), a novel synthetic compound with small-molecule drug properties, on androgen-regulated gene expression and cell growth in human prostate cancer cells. LNCaP, 22Rv1, and LAPC-4 cells were used

Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.

Masayasu Urushibara et al.

The Prostate, 67(8), 799-807 (2007-03-22)

Molecular basis for secondary antiandrogen therapy in prostate cancer with mutant androgen receptors (ARs) is not fully elucidated. Effects of steroidal and non-steroidal antiandrogens on transcriptional activities of wild-type and mutant (W741C, T877A, and W741C+T877A) ARs were measured. Crystal structure

Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

M G Harris et al.

Drugs & aging, 3(1), 9-25 (1993-01-01)

Nilutamide is a nonsteroidal antiandrogen with affinity for androgen receptors but not for progestogen, estrogen, or glucocorticoid receptors. Consequently, nilutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and cancerous prostatic tissue.

Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.